MARKET

PHR

PHR

Phreesia Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

69.18
+2.03
+3.02%
Closed 17:19 07/28 EDT
OPEN
67.24
PREV CLOSE
67.15
HIGH
69.95
LOW
67.24
VOLUME
263.73K
TURNOVER
--
52 WEEK HIGH
81.59
52 WEEK LOW
27.26
MARKET CAP
3.49B
P/E (TTM)
-90.2309
1D
5D
1M
3M
1Y
5Y
Phreesia to tap SEEK model to automate screening tool
Healthcare software company Phreesia (PHR) has partnered with the developers of the Safe Environment for Every Kid ((SEEK)) model to automate delivery of its screening tool.Phreesia's patient intake platform to
Seekingalpha · 6d ago
Phreesia Partners with Safe Environment for Every Kid (SEEK) to Automate Delivery of its Screening Tool
Phreesia is pleased to partner with the developers of the Safe Environment for Every Kid (SEEK) model to deliver their screening tool for adverse childhood experiences (ACEs) and negative social determinants of health (SDOH) to pediatric primary care provi...
Business Wire · 6d ago
Hedge Funds Are Crazy About Phreesia, Inc. (PHR)
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in re...
Insider Monkey · 07/13 16:38
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021
Upgrades
Benzinga · 07/13 14:13
Street sees green on psychedelic drug developers, and more in today's analyst action
adrian825/iStock via Getty Images Psychedelic drug developers started as buys Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald have initiated Atai Life Sciences ([[ATAI]] +2.3%) with  buy/overweight ratings. Credit Suisse
Seekingalpha · 07/13 14:09
JMP Securities Initiates Coverage On Phreesia with Market Outperform Rating, Announces Price Target of $80
JMP Securities analyst Joe Goodwin initiates coverage on Phreesia (NYSE:PHR) with a Market Outperform rating and announces Price Target of $80.
Benzinga · 07/13 11:16
Keybanc Maintains Overweight on Phreesia, Raises Price Target to $73
Keybanc analyst Donald Hooker maintains Phreesia (NYSE:PHR) with a Overweight and raises the price target from $70 to $73.
Benzinga · 07/12 08:48
KeyBanc Adjusts Phreesia's Price Target to $73 From $70, Keeps Overweight Rating
MT Newswires · 07/12 07:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PHR. Analyze the recent business situations of Phreesia Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PHR stock price target is 66.96 with a high estimate of 80.00 and a low estimate of 51.00.
EPS
Institutional Holdings
Institutions: 207
Institutional Holdings: 41.76M
% Owned: 82.65%
Shares Outstanding: 50.52M
TypeInstitutionsShares
Increased
69
4.70M
New
34
419.86K
Decreased
61
3.45M
Sold Out
25
1.45M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Software
+0.98%
Software & IT Services
+1.32%
Key Executives
Non-Executive Chairman/Independent Director
Michael Weintraub
Chief Executive Officer/Director
Chaim Indig
Chief Financial Officer
Randy Rasmussen
Chief Operating Officer
Evan Roberts
Senior Vice President/Director of Marketing
Michael Davidoff
Senior Vice President/Director of Human Resources
Amy VanDuyn
Senior Vice President/IR Contact Officer
Balaji Gandhi
Senior Vice President
David Linetsky
Chief Technology Officer
Daniel Nathan
General Counsel/Secretary
Allison Hoffman
Independent Director
Edward Cahill
Independent Director
Lainie Goldstein
Independent Director
Gillian Munson
Independent Director
Cheryl Pegus
Independent Director
Mark Smith
No Data
About PHR
Phreesia, Inc. is a United States-based healthcare software company. The Company provides healthcare organizations a suite of applications to manage the patient intake process and payment solution for patient payments. The Company provides software as a service platform which enables organizations to capture patient records and engage with patients. The Company’s software products enable appointments, registration, revenue cycle, patient surveys, patient activation, analytics and reports, and integration.

Webull offers kinds of Phreesia Inc stock information, including NYSE:PHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHR stock methods without spending real money on the virtual paper trading platform.